Tracon's carotuximab fails Phase II for RCC

Tracon Pharmaceuticals Inc. (NASDAQ:TCON) said carotuximab (TRC105) plus Inlyta axitinib missed the primary endpoint of improving progression-free survival (PFS) vs. Inlyta alone in the Phase II TRAXAR trial to treat advanced or metastatic renal cell carcinoma (RCC).

The open-label, international trial enrolled 150 patients who failed one prior VEGF inhibitor...